Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment landscape for HCC.
Megan Hollasch
Advertisement
Articles by Megan Hollasch
Although HER2 amplification showed prognostic capabilities in patients with RAS wild-type metastatic colorectal cancer (mCRC), it was not predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.
Advertisement
Latest Updated Articles
Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 RecommendationPublished: December 1st 2024 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
2
New WHO Reports Sounds Alarm on Antimicrobial Resistance
3
Responsible Use of Energy-Based Treatments on Skin of Color: Eliot F. Battle, MD
4
Value-Based Care Offers Solutions to Patient Access Challenges: Brian Mulherin, MD
5
